Form 4 for LXEO Lexeo Therapeutics, Inc.

Accepted 2023-11-09 00:00:00 ET · period of report 2023-11-07 · accession 0001209191-23-054910 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-11-09	2023-11-07	LXEO	McCormac Paul	Chief Technical Off	C - Cnv Deriv	—	+3,191	17.3K	+23%	—
D	2023-11-09	2023-11-07	LXEO	McCormac Paul	Chief Technical Off	C - Cnv Deriv	—	-29.1K	0	-100%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-11-07	C	A	3,191	—	17,349	D	—	—	(F1) Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.
2	Derivative	Series B convertible preferred stock	2023-11-07	C	D	29,061	—	0	D	— · — to —	3,191 Common Stock	(F1) Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.